Indian company receives emergency use approval for drug treatment of COVID-19

Sun Online Desk

4th May, 2021 10:28:31 printer

Indian company receives emergency use approval for drug treatment of COVID-19

Indian pharmaceutical company Natco Pharma has received an emergency-use approval for Baricitinib tablets from the Central Drugs Standard Control Organization to treat COVID-19 patients, the company said in a statement on Monday.

Prescribed originally for the treatment of rheumatoid arthritis, Baricitinib approved in strength of 1 mg, 2 mg and 4 mg is used in combination with Remdesivir drug to treat COVID-19 patients.

Natco, with annual revenue of 274 million U.S. dollars, will be requesting a Compulsory License from India's drug regulator based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic, the statement said.

The company, with six formulation manufacturing facilities across the country, is ready to launch the product this week. 

 

Source: Xinhua

 

Top